US equities
|
SPCX
$168.76
▲+6.17%
NVDA
$237.72
▲+1.61%
MU
$1,064.87
▼-0.93%
TSLA
$380.69
▲+2.73%
MSFT
$524.97
▲+1.44%
SNDK
$1,715.73
▼-0.25%
INTC
$116.87
▼-2.06%
META
$744.70
▲+2.28%
SPCX
$168.76
▲+6.17%
NVDA
$237.72
▲+1.61%
MU
$1,064.87
▼-0.93%
TSLA
$380.69
▲+2.73%
MSFT
$524.97
▲+1.44%
SNDK
$1,715.73
▼-0.25%
INTC
$116.87
▼-2.06%
META
$744.70
▲+2.28%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Aytu BioPharma, Inc. - Common Stock
(NQ:
AYTU
)
2.100
+0.030 (+1.45%)
Delayed Quote
Updated: 1:37 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aytu BioPharma, Inc. - Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Aytu BioPharma: Q3 Earnings Insights
↗
May 16, 2022
Aytu BioPharma (NASDAQ:AYTU) reported its Q3 earnings results on Monday, May 16, 2022 at 04:02 PM. Here's what investors need to know about the announcement. Earnings Aytu BioPharma beat estimated...
Via
Benzinga
Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities
May 16, 2022
Quarterly Net Revenue Increased 79% Year-Over-Year to $24.2 Million, the Highest Revenue in Company History Strategic Priorities Focused on Driving Revenue Growth, Increasing Financial Efficiencies and...
From
Aytu BioPharma, Inc.
Via
AccessWire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
April 27, 2022
Via
Benzinga
Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Delivery Technology
April 25, 2022
Preclinical Proof-of-Concept Study Demonstrates Effectiveness of Healight in Delaying Time to Development of Ventilator-Associated Pneumonia ENGLEWOOD, CO / ACCESSWIRE / April 25, 2022 / Aytu...
From
Aytu BioPharma, Inc.
Via
AccessWire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
↗
April 25, 2022
Another day of investing awaits for traders as we start it off with a breakdown of the biggest pre-market stock movers for Monday!
Via
InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
↗
April 22, 2022
Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) stock moved upwards by 16.8% to $1.32 during Friday's after-market session. The company's market cap stands at $37.0 million.
Via
Benzinga
54 Biggest Movers From Yesterday
↗
April 20, 2022
Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) shares jumped 325.9% to close at $10.35 on Tuesday after Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a deal to...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
April 19, 2022
Gainers Checkmate Pharmaceuticals (NASDAQ:CMPI) stock increased by 331.9% to $10.41 during Tuesday's regular session. Trading volume for Checkmate Pharmaceuticals'...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
April 19, 2022
Gainers Checkmate Pharmaceuticals (NASDAQ:CMPI) shares increased by 331.5% to $10.4 during Tuesday's pre-market session. The market value of their outstanding shares...
Via
Benzinga
Aytu BioPharma Announces Fast Track Designation Granted to AR101 for the Treatment of Vascular Ehlers-Danlos Syndrome
April 19, 2022
ENGLEWOOD, CO / ACCESSWIRE / April 19, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the U.S....
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT(R)
March 23, 2022
ENGLEWOOD, CO / ACCESSWIRE / March 23, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that its newly...
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Intellectual Property
Aytu BioPharma to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
March 22, 2022
ENGLEWOOD, CO / ACCESSWIRE / March 22, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that management...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma to Participate in the 34th Annual Roth Conference
March 08, 2022
ENGLEWOOD, CO / ACCESSWIRE / March 8, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that Mark Oki,...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma Announces Closing of $7.6 Million Registered Offering
March 07, 2022
ENGLEWOOD, CO / ACCESSWIRE / March 7, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the closing of...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma Announces Pricing of $7.6 Million Registered Offering
March 02, 2022
ENGLEWOOD, CO / ACCESSWIRE / March 2, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the placement to...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome
March 02, 2022
ENGLEWOOD, CO / ACCESSWIRE / March 2, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the European...
From
Aytu BioPharma, Inc.
Via
AccessWire
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
February 28, 2022
Gainers Soleno Therapeutics (NASDAQ:SLNO) shares rose 15.7% to $0.37 during Monday's pre-market session. The market value of their outstanding shares is at $29.5...
Via
Benzinga
Aytu BioScience's Return On Capital Employed Overview
↗
February 15, 2022
According to data from Benzinga Pro, during Q2, Aytu BioScience's (NASDAQ:AYTU) reported sales totaled $23.12 million. Despite a 58.54% increase in earnings, the company posted a loss of $11.55...
Via
Benzinga
The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics
↗
February 15, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage...
Via
Benzinga
Aytu BioPharma Announces Business and Pipeline Progress and Reports Second Quarter 2022 Financial Results
February 14, 2022
Quarterly Net Revenue Increased 53% Year-over-year to $23.1 Million PREVEnt Pivotal Study for AR101 in Vascular Ehlers-Danlos Syndrome On-track to Begin in Mid-2022 Initiation of Randomized,...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioScience, Inc. (NASDAQ:AYTU) Investor Alert: Investigation over Possible Violations of Securities Laws
↗
January 31, 2022
San Diego, CA -- (SBWIRE) -- 01/31/2022 -- An investigation was announced on behalf of investors of Aytu BioScience, Inc. (NASDAQ:AYTU) shares over potential securities laws violations by Aytu...
Via
SBWire
Aytu BioPharma Completes $15 Million Debt Refinancing
January 31, 2022
ENGLEWOOD, CO / ACCESSWIRE / January 31, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that it has...
From
Aytu BioPharma, Inc.
Via
AccessWire
12 Health Care Stocks Moving In Friday's After-Market Session
↗
January 28, 2022
Gainers Enveric Biosciences (NASDAQ:ENVB)...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
January 19, 2022
Gainers Acorda Therapeutics (NASDAQ:ACOR)...
Via
Benzinga
Aytu BioPharma Appoints Mark Oki as Chief Financial Officer
January 04, 2022
ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma to Present at H.C. Wainwright BioConnect Conference
January 03, 2022
ENGLEWOOD, CO / ACCESSWIRE / January 3, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today...
From
Aytu BioPharma, Inc.
Via
AccessWire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
December 14, 2021
Gainers Star Equity Hldgs (NASDAQ:STRR) s...
Via
Benzinga
Investigation Announced for Investors in NASDAQ:AYTU Shares of Possible Violations of Securities Laws by Aytu BioScience, Inc
↗
December 14, 2021
San Diego, CA -- (SBWIRE) -- 12/14/2021 -- Aytu BioScience, Inc is under investigation concerning potential securities laws violations in connection with certain financial statements.
Via
SBWire
Aytu BioPharma Announces FDA Clearance of Investigational New Drug (IND) Application for AR101/Enzastaurin in Vascular Ehlers-Danlos Syndrome
December 13, 2021
Pivotal clinical trial will begin in first half of 2022 ENGLEWOOD, CO / ACCESSWIRE / December 13, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel...
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome
December 08, 2021
ENGLEWOOD, CO / ACCESSWIRE / December 8, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,...
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Regulatory Compliance
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
